| 28.34 0.52 (1.87%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 37.11  |
1-year : | 40.14 |
| Resists | First : | 31.77 |
Second : | 34.37 |
| Pivot price | 29.75 |
|||
| Supports | First : | 27.56 |
Second : | 22.93 |
| MAs | MA(5) : | 28.73 |
MA(20) : | 30.33 |
| MA(100) : | 32.25 |
MA(250) : | 32.65 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 8.5 |
| RSI | RSI(14): 28.5  |
|||
| 52-week | High : | 40.71 | Low : | 27.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IMCR ] has closed above bottom band by 12.4%. Bollinger Bands are 8.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.31 - 29.47 | 29.47 - 29.65 |
| Low: | 27.18 - 27.36 | 27.36 - 27.55 |
| Close: | 27.48 - 27.79 | 27.79 - 28.13 |
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Mon, 12 Oct 2026
(IMCR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Sun, 11 Oct 2026
Immunocore Holdings plc (IMCR) stock price, news, quote and history - Yahoo Finance UK
Wed, 07 Oct 2026
One passive holder reports sole voting power over 1.73 million Immunocore (IMCR) shares. - Stock Titan
Tue, 06 Oct 2026
Price to earnings forward of Immunocore Holdings plc – NASDAQ:IMCR - TradingView
Tue, 29 Sep 2026
Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial (NASDAQ:IMCR) - Seeking Alpha
Fri, 07 Aug 2026
Immunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-08-07 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 103.1 (%) |
| Shares Short | 7,900 (K) |
| Shares Short P.Month | 7,790 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.14 |
| Profit Margin | -4.2 % |
| Operating Margin | -2.6 % |
| Return on Assets (ttm) | -0.2 % |
| Return on Equity (ttm) | -4.5 % |
| Qtrly Rev. Growth | 18.2 % |
| Gross Profit (p.s.) | 2.74 |
| Sales Per Share | 8.36 |
| EBITDA (p.s.) | 0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | 36 (M) |
| PE Ratio | -78.73 |
| PEG Ratio | 0 |
| Price to Book value | 3.47 |
| Price to Sales | 3.38 |
| Price to Cash Flow | -41.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|